More than 135 abstracts accepted for presentation across all phases of drug development

Dr. Ishwaria Subbiah to lead new programs focused on patient and clinical workplace experiences

Dr. Vivek Subbiah to serve as chief, early-phase drug development across SCRI's Research Network

SCRI and Mirati today announced a strategic partnership aimed at increasing diversity in clinical study recruitment practices.

Sarah Cannon Research Institute (SCRI), US Oncology Research (USOR), and Ontada announced that collectively more than 65 affiliated abstracts...

Harbinger Health, a biotechnology company pioneering the detection of early cancer, and Sarah Cannon Research Institute (SCRI) announced today...

Sarah Cannon Research Institute announced that it will highlight its latest cancer research insights through more than 140 abstracts and presentations...

Sarah Cannon recently announced that Sridhar Nuthi has been named Vice President of Engineering for Genospace.

Sarah Cannon
February 03, 2022

President Biden’s renewed focus on the Cancer Moonshot is welcome news.

Early-phase research expert, Cesar Perez, MD, leads the newest Sarah Cannon Research Institute at FCS drug development unit conveniently located...

Dr. Majhail will focus on the continued expansion of the Sarah Cannon Transplant and Cellular Therapy Network Centers of Excellence providing...

119 Abstracts and Presentations Featuring Sarah Cannon’s Clinical Research and Care Insights

Daiichi Sankyo and Sarah Cannon Research Institute announced that the first patient has been dosed in the first-in-human phase 1 study evaluating...

The consortium of prominent public and private research institutions will use HCA Healthcare’s vast data on COVID-19 hospital care to improve...

In her new role, Dr. Johnson will lead the lung cancer clinical trial portfolio across the Sarah Cannon network.

Sarah Cannon announced that 53 abstracts and presentations authored by Sarah Cannon experts have been selected for presentation at the upcoming...

The trusted cancer experts at Mission Health join HCA Healthcare’s Cancer Institute to enhance cancer services for patients across western North...

Advocacy Champions are ASCO volunteers who have made meaningful contributions to ASCO’s advocacy activities throughout the year to ensure that...

This partnership brings together Lyell’s research and development of cell-based immunotherapies and Sarah Cannon’s expertise in designing and...

Through the partnership, AON and Sarah Cannon will offer clinical trial options to patients across several locations within AON’s network of ...

More Than 110 Abstracts and Presentations will be Presented by Sarah Cannon Researchers; Dr. Howard A. “Skip” Burris III Serves as ASCO® President...

The first patient has been dosed in a first-in-human phase 1 study evaluating DS-6157, an investigational GPR20 directed antibody drug conjugate...

Recovered COVID-19 patients can donate plasma to potentially help critically-ill patients

The first patient has been dosed in a first-in-human phase 1/2 study evaluating DS-7300, an investigational B7-H3 targeting antibody drug conjugate...

NASHVILLE, TENN., May 30, 2019 – Today, Sarah Cannon announced that it will present its latest cancer research insights through more than 100...